Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1

The TZM-bl assay measures antibody-mediated neutralization of HIV-1 as a function of reductions in HIV-1 Tat-regulated firefly luciferase (Luc) reporter gene expression after a single round of infection with Env-pseudotyped viruses. This assay has become the main endpoint neutralization assay used f...

Full description

Saved in:
Bibliographic Details
Published inJournal of immunological methods Vol. 409; pp. 131 - 146
Main Authors Sarzotti-Kelsoe, Marcella, Bailer, Robert T., Turk, Ellen, Lin, Chen-li, Bilska, Miroslawa, Greene, Kelli M., Gao, Hongmei, Todd, Christopher A., Ozaki, Daniel A., Seaman, Michael S., Mascola, John R., Montefiori, David C.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.07.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The TZM-bl assay measures antibody-mediated neutralization of HIV-1 as a function of reductions in HIV-1 Tat-regulated firefly luciferase (Luc) reporter gene expression after a single round of infection with Env-pseudotyped viruses. This assay has become the main endpoint neutralization assay used for the assessment of pre-clinical and clinical trial samples by a growing number of laboratories worldwide. Here we present the results of the formal optimization and validation of the TZM-bl assay, performed in compliance with Good Clinical Laboratory Practice (GCLP) guidelines. The assay was evaluated for specificity, accuracy, precision, limits of detection and quantitation, linearity, range and robustness. The validated manual TZM-bl assay was also adapted, optimized and qualified to an automated 384-well format.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0022-1759
1872-7905
1872-7905
DOI:10.1016/j.jim.2013.11.022